OTCMKTS:VVUSQ VIVUS (VVUSQ) Stock Price, News & Analysis → SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad) Free VVUSQ Stock Alerts $0.12 0.00 (0.00%) (As of 12/17/2020) Add Compare Share Share Today's Range$0.12▼$0.1250-Day Range$0.12▼$0.1252-Week Range$0.07▼$4.55VolumeN/AAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get VIVUS alerts: Email Address Ad Priority GoldBiden to Launch “FedNOW” [Move Your Money Now]Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentially cancel your money. You see Biden and the Fed have teamed up to create a controllable, traceable, programmable digital currency to replace the dollar...Get your free information kit NOW, before it's too late. About VIVUS Stock (OTCMKTS:VVUSQ)VIVUS, Inc. operates as a specialty pharmaceutical company primarily in the United States and the European Union. The company offers Qsymia for the treatment of obesity as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body-mass index of 30 or greater (obese patients) or 27 or greater (overweight patients) in the presence of at least one weight-related comorbidity, such as hypertension, type 2 diabetes mellitus, or high cholesterol. It also provides PANCREAZE to treat exocrine pancreatic insufficiency due to cystic fibrosis, chronic pancreatitis, pancreatic cancer or other conditions; and STENDRA/SPEDRA, an oral phosphodiesterase type 5 inhibitor for erectile dysfunction. In addition, the company is developing Qsymia, which has completed Phase II clinical study for treating various diseases, including obstructive sleep apnea, diabetes, nonalcoholic steatohepatitis, and bariatric surgery; and VI-0106 that has completed Phase IIa study to treat patients with pulmonary arterial hypertension. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation; Menarini Group; Sanofi; Metuchen Pharmaceuticals, LLC; Selten Pharma, Inc.; and Alvogen Malta Operations (ROW) Ltd. VIVUS, Inc. was founded in 1991 and is headquartered in Campbell, California. On July 7, 2020, VIVUS, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.Read More VVUSQ Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart VVUSQ Stock News HeadlinesApril 12, 2024 | uk.finance.yahoo.comAnti-obesity Drugs market is estimated to grow at a CAGR of 21.2% by 2034: VisiongainFebruary 28, 2024 | msn.comUS pharma giant Eli Lilly plans to introduce its blockbuster anti-diabetes drug Mounjaro to India next year, to target weight loss marketApril 18, 2024 | Priority Gold (Ad)Biden to Launch “FedNOW” [Move Your Money Now]Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentially cancel your money. You see Biden and the Fed have teamed up to create a controllable, traceable, programmable digital currency to replace the dollar...February 9, 2024 | msn.comWeight-loss drugs for teens are controversial. A 16-year-old taking Wegovy shares her storyJanuary 27, 2024 | msn.comThe First Porsche With All-Wheel Drive Was An Off-Road Military VehicleJanuary 5, 2024 | msn.comNorovirus, aka stomach flu, on the rise in the US: Know these signsDecember 30, 2023 | bbc.co.ukGustav Mahler: Eighth Symphony: Part TwoDecember 23, 2023 | msn.comWhy pharma majors are rushing to put anti-obesity drugs on Indian shelvesApril 18, 2024 | Priority Gold (Ad)Biden to Launch “FedNOW” [Move Your Money Now]Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentially cancel your money. You see Biden and the Fed have teamed up to create a controllable, traceable, programmable digital currency to replace the dollar...December 14, 2023 | finance.yahoo.comErectile Dysfunction (ED) Drugs Market to grow by USD 1.44 billion from 2023-2028, North America to account for 41% of market growth - TechnavioDecember 7, 2023 | ca.news.yahoo.comCaledon residents donate $500,000 to Headwaters Health Care FoundationDecember 7, 2023 | ca.sports.yahoo.comWhat Is Barre? Everything to Know About This Low-Impact, High-Intensity WorkoutDecember 7, 2023 | ca.sports.yahoo.comTeens who use phones for over 4 hours daily face higher health risks: studyDecember 7, 2023 | ca.sports.yahoo.comCharlotte hospitals change visitor guidelines due to rising COVID-19, flu and RSV casesDecember 7, 2023 | ca.news.yahoo.comHospital Pushed Weight-Loss Surgery on Prisoners Who Recovered in Jail: NYTDecember 6, 2023 | ca.sports.yahoo.comFree at-home testing and treatments now available for COVID and flu through federal programDecember 6, 2023 | ca.news.yahoo.comSaskatchewan auditor reports longer waits for neurosurgeries; more homelessnessDecember 6, 2023 | ca.sports.yahoo.comBoris Johnson admits he should 'twigged the risk' of Covid earlierDecember 6, 2023 | ca.news.yahoo.comThis Is How I Finally Got My Tubes Removed After Years Of Doctors Fighting Me On ItDecember 6, 2023 | reuters.comAdherence to weight-loss drugs is far higher with Wegovy than older medicinesOctober 3, 2023 | finance.yahoo.comAnti-Obesity Drugs Market is forecasted to reach USD 8.2 billion by 2032, growing at a 14.6% CAGR from 2023 to 2032September 28, 2023 | reuters.comWegovy, other weight-loss drugs scrutinized over reports of suicidal thoughtsSeptember 1, 2023 | msn.comEU regulators warn pregnant women not to use topiramateAugust 31, 2023 | msn.comStudy finds Wegovy least cost-effective drug option for teen weight lossJuly 10, 2023 | theglobeandmail.comEU investigates Ozempic, weight-loss drug Saxenda after patients report suicidal thoughtsJuly 10, 2023 | nbcnews.comE.U. investigates Ozempic and weight-loss drug Saxenda after reports of suicidal thoughtsJuly 10, 2023 | msn.comEU investigates Ozempic, weight-loss drug Saxenda after suicidal thoughts reportedSee More Headlines Receive VVUSQ Stock News and Ratings via Email Sign-up to receive the latest news and ratings for VIVUS and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today4/18/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolOTCMKTS:VVUSQ CUSIPN/A CIKN/A Webwww.vivus.com Phone650-934-5200Fax650-934-5389Employees59Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesMr. John P. Amos (Age 53)CEO, Pres & Director Comp: $556.2kMr. Mark K. Oki (Age 51)Sr. VP, CFO & Chief Accounting Officer Comp: $422.2kMr. John L. Slebir (Age 55)Sr. VP of Bus. Devel., Gen. Counsel & Sec. Comp: $632.7kDr. Santosh T. Varghese (Age 50)Sr. VP & Chief Medical Officer Comp: $555.44kMs. Deborah LarsenChief Strategy Officer - Commercial OperationsKey CompetitorsAbliva AB (publ)OTCMKTS:NEVPFAcusphereOTCMKTS:ACUSAddex TherapeuticsOTCMKTS:ADDXFAeolus PharmaceuticalsOTCMKTS:AOLSAffymaxOTCMKTS:AFFYView All Competitors VVUSQ Stock Analysis - Frequently Asked Questions How have VVUSQ shares performed in 2024? VIVUS's stock was trading at $0.1174 at the start of the year. Since then, VVUSQ shares have increased by 0.0% and is now trading at $0.1174. View the best growth stocks for 2024 here. How do I buy shares of VIVUS? Shares of VVUSQ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:VVUSQ) was last updated on 4/18/2024 by MarketBeat.com Staff From Our PartnersSHOCKING Crypto Leak…Crypto 101 MediaBiden’s $374B Giveaway Into This SectorDTIThe “Perfect Storm” for GoldGold Safe ExchangeDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTop 5 AI Stocks to Buy for 2024Market Moving TrendsHow Biden has already won 2024Porter & CompanyTop 5 Tech Stocks to Buy for 2024Daily Market AlertsMan Who Predicted 2008: “This Will be Worse.”Altimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding VIVUS, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.